The Tiny Biotech That Thinks It Can Beat Pfizer at Prostate Cancer
A small biotech called Oric Pharmaceuticals is heading into a massive Phase 3 trial for prostate cancer, armed with preclinical data showing its drug outperforms Pfizer's rival molecule. The $16 billion prostate cancer market just got a lot more interesting.
David Picks Up a Slingshot
Oric Pharmaceuticals has a market cap smaller than some Manhattan apartment buildings. Pfizer pulls in more revenue before lunch on a Tuesday than Oric has ever generated in its history. And yet, Oric just walked up to the podium and essentially said: we think our drug is better than yours.
The South San Francisco biotech is gearing up to launch a global Phase 3 trial for its prostate cancer drug, rinzimetostat, in the first half of 2026. The trial, called SYMPHONY-1, will enroll roughly 600 patients across more than 250 sites in over 20 countries. That's a massive bet for a company this size. And the reason they're making it? Preclinical data suggesting rinzimetostat outperforms Pfizer's own competing molecule when combined with standard treatments.
Bold claim. Let's unpack it.
The Science (Without the PhD)
Prostate cancer is the second most common cancer in men worldwide. When it advances to a stage called metastatic castration-resistant prostate cancer (mCRPC), the tumor has essentially learned to ignore the hormonal therapies designed to starve it. Think of it like a weed that figured out how to survive your weed killer. At that point, options get limited and outcomes get worse.
Most current drugs for mCRPC target the androgen receptor (AR), which is the molecular switch that testosterone flips to fuel tumor growth. The problem: tumors eventually evolve to dodge these drugs too. They undergo something called lineage plasticity, basically shapeshifting at the cellular level to become something that AR-targeting drugs can't touch.
This is where Oric's rinzimetostat comes in. Instead of going after the androgen receptor directly, it targets a protein complex called PRC2 by binding to its EED subunit. In plain English, it resets the tumor's identity. It forces cancer cells back into a state where they're vulnerable to AR-targeting drugs again. It's like un-teaching the weed how to resist your weed killer, then spraying it all over again.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Pfizer has its own PRC2 inhibitor, called PF-06821497, which attacks the complex from a different angle (the EZH2 subunit instead of EED). Same target family, different door. And according to Oric's preclinical studies, rinzimetostat showed better antitumor activity than Pfizer's molecule when paired with AR inhibitors across multiple prostate cancer models.
The Numbers That Got Wall Street's Attention
Oric's Phase 1b trial tested rinzimetostat in combination with AR inhibitors (darolutamide and apalutamide) in mCRPC patients who had already been through the wringer with prior treatments. The results, while early, turned heads.
59% of patients achieved a PSA50 response, meaning their PSA levels (a key marker for prostate cancer activity) dropped by at least half. That's a strong signal in a patient population where tumors have already proven they can dodge existing therapies.
Even more impressive: among patients with detectable circulating tumor DNA (ctDNA) at baseline, 59% achieved complete ctDNA clearance. ctDNA is essentially cancer's molecular breadcrumbs floating in the bloodstream. Clearing it suggests the drug isn't just slowing things down; it's potentially cleaning house.
Safety looked manageable too. Most side effects were Grade 1 or 2, the medical equivalent of "annoying but livable." For a drug designed to be taken long-term alongside other therapies, that matters enormously.
What SYMPHONY-1 Needs to Prove
Phase 1b data is encouraging, but it's a small sample (17 evaluable patients at the latest cutoff). The real test comes with SYMPHONY-1, the registrational Phase 3 trial that could lead to FDA approval.
The trial will randomize roughly 600 patients who've already been treated with abiraterone (a standard AR-targeting therapy) into two groups. One gets rinzimetostat at 400mg daily plus darolutamide. The other gets physician's choice, either a different AR inhibitor or chemotherapy.
The primary endpoint is radiographic progression-free survival (rPFS), which measures how long patients go before their cancer visibly worsens on imaging scans. Secondary endpoints include overall survival, PSA response rates, and patient-reported outcomes.
In clinical trial terms, this is Oric putting its chips in the middle of the table. A global, 600-patient, 250-site registrational study is expensive, complex, and unforgiving. If it works, Oric could become a major player in a prostate cancer market estimated at $16 billion in 2025 and projected to nearly double by the mid-2030s. If it doesn't, well, the biotech graveyard is full of promising Phase 1b stories.
The Competitive Chessboard
Oric isn't just up against Pfizer here. The mCRPC space is getting crowded with creative new approaches. Novartis picked up rights to ARV-766 (luxdegalutamide), a next-generation AR degrader from Arvinas, for $150 million upfront plus over a billion in potential milestones. That drug works by physically destroying the androgen receptor rather than just blocking it, like shredding the lock instead of changing the key.
Then there's Novartis's Pluvicto, a radioligand therapy that delivers radiation directly to PSMA-positive tumors, which won FDA approval in March 2022 and received a label expansion in March 2025. AbbVie is testing a dual-targeted antibody-drug conjugate called ABBV-969. The list goes on.
But Oric's angle is genuinely different. While most competitors are finding new ways to attack the androgen receptor or deliver payloads to tumor cells, Oric is trying to reverse the resistance mechanism itself. If rinzimetostat can reliably re-sensitize tumors to existing drugs, it doesn't just compete with these therapies; it potentially makes them work better.
What Analysts Are Saying
Wall Street is cautiously optimistic. JPMorgan reiterated an Overweight rating with a $21 price target. Jones Trading maintained a Buy at $17. The stock has been trading in the low-to-mid teens recently, which means analysts see significant upside if things go right.
Not everyone is fully on board. Wolfe Research rated the stock Peerperform (translation: "meh, we'll watch"), citing concerns about safety signals seen with related drugs in the EZH2 inhibitor class, specifically secondary blood cancers that showed up in a competitor's trial.
That's a legitimate worry, and one Oric will need to address with long-term safety data from SYMPHONY-1. The company says its drug has a differentiated safety profile, with a clinical half-life of about 20 hours and a side-effect profile compatible with chronic use. The Phase 3 trial will be the proving ground.
The Bottom Line
Oric Pharmaceuticals is doing something rare in biotech: picking a fight with a giant and backing it up with data. The preclinical head-to-head comparisons with Pfizer's molecule, the promising (if early) clinical results, and the ambitious SYMPHONY-1 trial design all suggest this isn't just hype.
But Phase 3 trials are where dreams go to get stress-tested. A 600-patient global study is a marathon, not a sprint, and the mCRPC competitive landscape won't sit still while Oric runs it. The company says it has cash runway into the second half of 2028, which should cover the trial timeline.
For now, the slingshot is loaded. Whether it actually hits Goliath is a question only SYMPHONY-1 can answer.
Clinical & Regulatory4 min read
From $100M IPO to Liquidation in Five Years
IO Biotech went from a $100M IPO and "most innovative biotech" honors to total Chapter 7 liquidation in five years, all because its cancer vaccine trial missed statistical significance by the thinnest of margins. It's the most brutal cautionary tale in immuno-oncology right now.
